Figure - available from: BMC Cancer
This content is subject to copyright. Terms and conditions apply.
The assessment and validation of ENO2 as a prognostic factor. A Immuno-histochemical staining of ENO2 protein in MSI-H CRC tissue and adjacent normal tissue (Scale bar, 50 μm). B Nomogram for predicting the death of MSI-H CRC patients. C Calibration plot of the nomogram. D The ROC curve to predict the death of MSI-H CRC patients based on the nomogram
Source publication
Background
Microsatellite instability-high (MSI-H) has emerged as a significant biological characteristic of colorectal cancer (CRC). Studies reported that MSI-H CRC generally had a better prognosis than microsatellite stable (MSS)/microsatellite instability-low (MSI-L) CRC, but some MSI-H CRC patients exhibited distinctive molecular characteristic...
Citations
... ENO2, primarily located in mature neurons, was the first enzyme identified in mammals and has been reported to show elevated expression in tumors like glioblastoma (36), neuroendocrine prostate carcinoma (37), and renal cell carcinoma (38). Recent evidence also supports ENO2's role in shaping the tumor immune microenvironment, particularly through neutrophil recruitment (39). In contrast to prior studies, our data reveal that ENO2's association with dendritic cell infiltration in COAD may enhance antigen presentation, providing a mechanistic rationale for its inclusion in mRNA vaccine design. ...
Background
Colon cancer is a prevalent malignancy that significantly threatens human health. In recent years, mRNA cancer vaccines have demonstrated considerable potential and distinct advantages in colon cancer treatment. Thus, This study identifies CUL7, ENO2, and MPP2 as potential antigens for colon cancer mRNA vaccines. Through multi-omics analysis, we classify COAD into three immune subtypes (C1-C3) with distinct molecular and clinical features.
Methods
Data from TCGA and GEO databases were analyzed using bioinformatics tools. Prognostic indices were calculated with GEPIA2, and TIMER assessed antigen-presenting cell infiltration. Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards models. Immune subtypes were classified via non-negative matrix factorization (NMF) clustering, with k=3 determined by cophenetic correlation (0.92) and silhouette width (average = 0.85). Drug sensitivity, immune cell infiltration, and gene set variation were analyzed using R packages such as “pRRophetic,” CIBERSORT, and GSVA. Functional enrichment analysis was performed with GO, KEGG, and GSEA. Experimental validation included immunohistochemistry and RT-PCR to confirm gene expression.
Results
Analysis of TCGA-COAD data revealed copy number variants in 16,354 genes, with CUL7, ENO2, and MPP2 showing significant antigen-presenting cell infiltration and associations with overall survival (OS) and relapse-free survival (RFS). Based on molecular mechanisms, cellular features, and clinical characteristics, colon cancer was categorized into three immune subtypes (C1, C2, and C3) distinct from Thorsson’s pan-cancer subtypes (C1-C6) in pathway enrichment, with the C2 subtype exhibited significantly longer overall survival (OS) than C1 and C3 (median OS: C2 = 68 months vs. C1 = 42 months, C3 = 37 months; log-rank P < 0.001). The distribution of these immune subtypes showed disparities in immune patterns, and a correlation between key components and immune cells was observed. Prognostic correlation analysis indicated that the gray and turquoise modules were closely linked to colorectal cancer prognosis. Additionally, RT-PCR confirmed the association of CUL7, ENO2, and MPP2 expression levels with colon cancer.
Conclusions
CUL7, ENO2, and MPP2 were identified as potential antigens for colon cancer mRNA vaccines, with MPP2 showing particular immunological relevance. This study provides a foundation for mRNA vaccine development and patient stratification for vaccination in colon cancer.
